Assembling evidence grade
Loading
Independent evidence before payment.
Synthetic peptide fragment · also: Body Protection Compound 157, PL 14736
BPC-157 carries an Evidence Grade of F (Low confidence). The strongest published evidence catalogued is mechanistic.
Grade F rule: In-vitro / mechanistic only, or none.
The grade reflects the strength of the published evidence, not safety or efficacy. “Confidence” means how settled that grade is given the record — not how likely the compound is to work.
Human-use stop
This compound is investigational, warned or not approved for human use. A seller calling it “research only,” showing testimonials, registering a company or publishing a COA does not create an approved consumer medicine. Seller links below are market-surveillance records, not recommendations.
BPC-157 is a synthetic peptide derived from a gastric protein. Most published work is preclinical — animal and in-vitro models of tissue repair — with limited human data.
Animal and in-vitro results are shown separately and must never be read as established human outcomes.
In plain terms: this is lab-bench work only — 12 studies in cells or proposed mechanisms, with no animal or human trials. That is the weakest tier of evidence there is.
Strongest: randomised or pooled human trials.
none catalogued
Observational, open-label or small human studies.
none catalogued
Preclinical animal models — not a human outcome.
none catalogued
Cell / tissue studies — not a human outcome.
none catalogued
Proposed mechanism — hypothesis, not evidence of effect.
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.), 2026.
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American journal of sports medicine, 2026.
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026.
Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 2025.
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current reviews in musculoskeletal medicine, 2025.
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025.
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel, Switzerland), 2025.
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in pharmacology, 2021.
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative therapies in health and medicine, 2021.
Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and tissue research, 2019.
BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current pharmaceutical design, 2018.
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of applied physiology (Bethesda, Md. : 1985), 2011.
On “cited by N”: citation counts (Crossref) reflect how often a paper has been referenced — a measure of academic attention, not of validity, safety, or whether a compound works. They do not affect the Evidence Grade, which is set purely by the strength of the evidence tier.
Human evidence is scarce. Animal and in-vitro findings must not be read as established human outcomes. No approved formulation exists.
Not an approved medicine in major markets. Sold only as a “research chemical”, with no established safe consumer use, dose or supply standard.
PepCred flags any vendor selling this compound to the public as a consumer-protection concern. Status reflects regulator records; see the regulatory detail below.
Registered studies:
No FDA-approved (US) drug labelling found for this compound. A search of openFDA returned no approved product containing it as an active ingredient.
This reflects US FDA approval only — other regulators (e.g. MHRA, EMA) may differ; see the note below. Absence of an approved label is not, by itself, a safety finding, and a “research use only” label does not establish safety, legality or correct identity.
PepCred note: Not approved; flagged by some regulators as not for human use.
FDA lists BPC-157 in category 2 and describes potential significant safety risks for compounded products.
These unranked records show where the name was detected. For an investigational, warned or unapproved compound, no seller, company registration, review score or COA creates an approved human-use route.
None of these is verified for human use.